Which adverse effect unique to vancomycin is caused by histamine release?

A. Decision to administer either a bactericidal or bacteriostatic drug:

Culture and sensitivity tests provide information about the susceptibility of the microorganism to specific antimicrobial agents. Based on this information, healthcare providers can choose between bactericidal (agents that kill bacteria) or bacteriostatic (agents that inhibit bacterial growth) drugs. For example, if the culture indicates that the microorganism is susceptible to a bactericidal drug, such as penicillin, the healthcare provider may choose to administer that type of drug.

B. Microbial susceptibility to an anti-infective:

This option accurately describes one of the primary purposes of culture and sensitivity tests. These tests determine whether the microorganism causing the infection is susceptible or resistant to specific antimicrobial agents. This information guides the selection of the most appropriate anti-infective therapy to effectively treat the infection.

C. Duration of the antibacterial drug therapy:

While culture and sensitivity tests provide valuable information about microbial susceptibility to antimicrobial agents, they do not specifically determine the duration of antibacterial drug therapy. The duration of therapy is often determined based on factors such as the type and severity of the infection, the patient's response to treatment, and clinical guidelines, rather than solely on the results of culture and sensitivity tests.

D. Decision to administer empiric therapy:

Empiric therapy involves the initiation of antimicrobial treatment based on clinical judgment and knowledge of likely pathogens before culture and sensitivity results are available. Culture and sensitivity tests help confirm the causative microorganism and guide subsequent treatment decisions, including adjustments to therapy based on the results. Therefore, while culture and sensitivity tests inform decisions regarding antimicrobial therapy, they do not directly determine whether empiric therapy should be initiated.

A. The patient stops taking the drug when he or she begins to feel better:

This choice refers to the common habit where patients discontinue their prescribed medication once they start to feel improvement in their symptoms, even if they haven't completed the full course of treatment. This premature cessation of medication can leave some microbes alive and potentially resistant to the antibiotic, allowing them to regrow and cause a recurrence of the infection.

B. The patient switches to multiple drug therapy from single drug therapy:

This choice describes a scenario where a patient switches from a single drug therapy to multiple drug therapy. While this may be a valid treatment approach in some cases, it is not directly related to the re-population and re-establishment of microbes causing an infection.

C. The patient uses OTC drugs prophylactically:

This choice involves patients using over-the-counter (OTC) drugs preventively without consulting a healthcare professional. While OTC drugs may have their own set of issues, such as contributing to antibiotic resistance, this behavior isn't specifically linked to the re-population and re-establishment of microbes causing an infection.

D. The patient increases the drug dosage when he or she perceives that the therapeutic effect of the drug is slowing down:

This choice describes a scenario where a patient independently increases the dosage of their medication without consulting a healthcare provider. While inappropriate dosage adjustments can lead to adverse effects, it doesn't directly address the re-population and re-establishment of microbes causing an infection.